Hemangioma Market Research Report - Global Forecast To 2023

Report / Search Code: MRFR/HC/2349-HCRR
Publish Date: September, 2018

Price

1-user PDF : $ 4450.0
Enterprise PDF : $ 6250.0

Description:

Global Hemangioma Market information, by type (Capillary hemangioma, Cavernous hemangioma, Compound hemangioma, Lobular capillary hemangioma (pyogenic granuloma), and others), by diagnosis (Ultrasound, MRI, CT scan, and others), by Treatment (medical therapies, laser therapy, surgery) - Forecast to 2023

Market Synopsis of Global Hemangioma Market:

Market Scenario:

Hemangioma is the birthmark or benign tumors of infancy that occurs due to an abnormal collection of blood vessels. This occurs in 5-10% of infants worldwide. Increasing cases of hemangioma, increasing use of technology, and different treatment options are key drivers for the global Hemangioma market. Increasing knowledge about the disorder and treatment, introduction of new drugs and therapies, and rapidly changing medical technology are major driving forces of the global hemangioma market. Increasing investment in R&D to develop more advanced product for the market is another major factor for the market.

The Global Hemangioma market is growing at the CAGR of ~3.2% during the forecast period and expected to reach US$ 294.8 million by 2023.

Study objectives of Global Hemangioma Market:

- To provide detailed analysis of the Global Hemangioma market structure with historical and forecast revenue for the next 7 years of the various segments and sub-segments of the Hemangioma market
- To provide insights about the key drivers, restraints, opportunities and challenges that affecting the growth of the Hemangioma market
- To provide analysis of the market with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.
- To provide detail analysis of the market that segmented on the basis of type, by diagnosis, by treatment, and its sub-segments.
- To provide detail analysis of global Hemangioma market mainly based on value chain analysis, Porter’s five forces, Price analysis, and Supply Chain analysis etc.
- To provide detail country level analysis of the market with respect to the current market size and future prospective
- To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Global Hemangioma Market
- To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the Hemangioma market

FIGURE 1

GLOBAL HEMANGIOMA MARKET SHARE, BY DIAGNOSIS (%)
Key Players for Global Hemangioma Market:

Some of the key players in this market are: Akrimax Pharmaceuticals, LLC. (US), AstraZeneca (UK), Cutting Edge Laser Technologies (US), Linline Medical Systems (France), Novartis AG (Switzerland), Pfizer Inc. (US), Pierre Fabre (US) Quanta System S.p.A. (Italy), and others.

Segments:

Global Hemangioma Market has been segmented on the basis of type which Capillary hemangioma, Cavernous hemangioma (Cerebral cavernous malformations, Liver cavernous hemangioma, Eye cavernous hemangioma), Compound hemangioma, Lobular capillary hemangioma (pyogenic granuloma), and others. Cavernous hemangioma is further sub-segmented into cerebral cavernous malformations, liver cavernous hemangioma, and Eye cavernous hemangioma.

On the basis of diagnosis, it is segmented into Ultrasound, MRI, CT scan, and others.

On the basis of treatment, the market is segmented into medical therapy, laser therapy, surgery, and others. Medical therapy is further sub-segmented into systemic, intralesional and topical. Laser therapy is sub-segmented into Flash lamp pulsed dye laser, intralesional laser, carbon dioxide laser.

Research Methodology:

Sources: Directorate of Industries, Annual report, White paper, Company Presentation

Regional Analysis of Global Hemangioma Market:

Considering the global scenario of the market, due to continuous innovation and rapid adoption of new drugs and therapies, North America is holding largest market for Hemangioma. In North America region, US attributes largest market share. European market is second largest, and especially the growth rate is higher in west European countries. On the other hand, developing healthcare infrastructure, and increasing healthcare spending, the Asia-Pacific (APAC) is fastest growing market for Hemangioma and expected to grow significantly during the forecast period. Middle East and Africa (ME&A) is likely to have a limited growth in the market due to less awareness of treatment and products.

The report for Global Hemangioma Market of Market Research Future comprises extensive primary research along
with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions

**Intended Audience**

- Hemangioma medicines and devices manufacturers
- Hemangioma medicines and devices providers
- Hospitals and clinics
- Medical Research laboratories
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Potential Investors

**Contents:**

1. Report Prologue

2. Introduction

   2.1 Definition
   2.2 Scope of the Study
   2.2.1 Research Objective
   2.2.2 Assumptions
   2.2.3 Limitations

3. Market Structure

4. Market Segmentation

3. Research Methodology

   3.1 Research Process
   3.2 Primary Research
   3.3 Secondary Research
   3.4 Market Size Estimation
   3.5 Forecast Model

4. Market Dynamics

   4.1 Drivers
   4.2 Restraints
   4.3 Opportunities
   4.4 Mega Trends
   4.5 Macroeconomic Indicators

5. Market Factor analysis

   5.1 Value Chain Analysis
   5.2 Porters Five Forces
   5.3 Demand & Supply: Gap Analysis
   5.4 Pricing Analysis
   5.5 Investment Opportunity Analysis
5.6 Merger and Acquisition Landscape

5.7 Upcoming trends

5.7.1 Market trends

5.7.2 Technological trends

5.7.3 Insurance & Regulations

5.7.4 Others

6. Global Hemangioma Market by Type

6.1 Capillary hemangioma

6.2 Cavernous hemangioma

6.2.1 Cerebral cavernous malformations

6.2.2 Liver cavernous hemangioma

6.2.3 Eye cavernous hemangioma

6.3 Compound hemangioma

6.4 Lobular capillary hemangioma (pyogenic granuloma)

6.5 Others

7. Global Hemangioma Market by Diagnosis

7.1 Ultrasound

7.2 MRI

7.3 CT scan

7.4 Others

8. Global Hemangioma Market by Treatment

8.1 Medical therapies

8.1.1 Systemic

8.1.2 Intralesional

8.1.3 Topical

8.2 Laser therapy

8.2.1 Flash lamp pulsed dye laser

8.2.2 Intralesional laser

8.2.3 Carbon dioxide laser

8.3 Surgery

8.4 Others

9. Global Hemangioma Market by Region

9.1 Introduction

9.2 America

9.2.1 North America

9.2.1.1 The US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 Italy
9.3.1.3 Spain
9.3.1.5 UK
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia
9.4.1 China
9.4.2 India
9.4.3 Japan
9.4.4 South Korea
9.4.5 Rest of Asia
9.5 Pacific
9.6 Middle East and Africa
9.6.1 UAE
9.6.2 Saudi Arabia
9.6.3 Egypt
9.6.4 Rest of Middle East and Africa
10. Competitive landscape
11. Company profile
11.1 Akrimax Pharmaceuticals, LLC.
11.1.1 Company Overview
11.1.2 Type/Business Segment Overview
11.1.3 Financial Updates
11.1.4 Key Developments
11.2 AstraZeneca
11.2.1 Company Overview
11.2.2 Type/Business Segment Overview
11.2.3 Financial Updates
11.2.4 Key Developments
11.3 Cutting Edge Laser Technologies
11.3.1 Company Overview
11.3.2 Type/Business Segment Overview
11.3.3 Financial Updates
11.3.4 Key Developments
11.4 Linline Medical Systems
11.4.1 Company Overview
11.4.2 Type/Business Segment Overview
11.4.3 Financial Updates
11.4.4 Key Developments
11.5 Pfizer Inc.

11.5.1 Company Overview

11.5.2 Type/Business Segment Overview

11.5.3 Financial Updates

11.5.4 Key Developments

11.6 Others

12 Conclusion

12.1 Key findings

12.1.1 From CEO’s viewpoint

12.1.2 Unmet needs of the market

12.2 Key companies to watch

12.3 Prediction of Hemangioma Market

13 Appendix